Tweet
Blair William & Co. IL cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.3% in the 1st quarter, HoldingsChannel reports. The fund owned 912,169 shares of the biopharmaceutical company's stock after selling 50,757 shares during the period. Blair William & Co. IL's holdings in Pfizer were worth $32,373,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in PFE. BlackRock Inc. lifted its position in shares of Pfizer by 1.5% during the first quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company's stock worth $16,308,754,000 after purchasing an additional 6,785,335 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Pfizer by 11.9% during the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company's stock worth $2,562,162,000 after purchasing an additional 7,534,957 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Pfizer by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company's stock worth $2,281,563,000 after purchasing an additional 1,881,570 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Pfizer by 1.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 61,720,550 shares of the biopharmaceutical company's stock worth $2,190,462,000 after purchasing an additional 889,094 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Pfizer by 11.9% during the first quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company's stock worth $1,674,223,000 after purchasing an additional 4,998,981 shares during the last quarter. Institutional investors own 69.28% of the company's stock. Get Pfizer alerts:
In other Pfizer news, insider Alexander R. Mackenzie sold 25,642 shares of the firm's stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $39.51, for a total value of $1,013,115.42. Following the sale, the insider now owns 127,954 shares in the company, valued at $5,055,462.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Also, Director W Don Cornwell sold 5,223 shares of the firm's stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $36.40, for a total transaction of $190,117.20. The disclosure for this sale can be found here . Insiders sold 785,453 shares of company stock worth $29,937,357 in the last 90 days. 0.06% of the stock is owned by company insiders. Several equities analysts have recently commented on the stock. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a "buy" rating in a research report on Monday. Zacks Investment Research cut shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, July 15th. SunTrust Banks increased their price target on shares of Pfizer to $41.00 and gave the stock a "hold" rating in a research report on Friday, August 10th. Morningstar set a $45.00 price target on shares of Pfizer and gave the stock a "buy" rating in a research report on Wednesday, August 8th. Finally, Bank of America raised their target price on shares of Pfizer from $42.00 to $43.00 and gave the stock a "buy" rating in a report on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The company has a consensus rating of "Hold" and an average price target of $40.95.
Shares of NYSE PFE opened at $41.42 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a 52-week low of $32.32 and a 52-week high of $41.64. The stock has a market capitalization of $243.65 billion, a price-to-earnings ratio of 15.63, a price-to-earnings-growth ratio of 1.98 and a beta of 0.96.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm had revenue of $13.47 billion for the quarter, compared to analysts' expectations of $13.30 billion. During the same quarter last year, the company posted $0.67 earnings per share. Pfizer's revenue was up 4.4% on a year-over-year basis. analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd will be paid a $0.34 dividend. The ex-dividend date is Thursday, August 2nd. This represents a $1.36 annualized dividend and a dividend yield of 3.28%. Pfizer's payout ratio is currently 51.32%.
About Pfizer
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Article: Dividend Stocks â€“ Are They Right For You?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE). Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter 